Investment blog Seeking Alpha points out that Johnson & Johnson’s decision to stop selling four types of vaginal mesh implants is the latest example of the company’s loose approach to product safety, and should be of concern to potential investors.
“While the New Jersey pharmaceutical giant stressed that the devices are safe, investors have had warning signs for years about J&J’s high risk of running into cross hairs with regulators,” the blog states.
Last week, Johnson & Johnson announced that it would ...
continue reading...
The American College of Obstetricians and Gynecologists says pregnant women who are suffering symptoms of depression must consider the consequences of treatment.
A story in the Toledo Blade from Ohio mentions the 
Bloomberg reports on a study that suggests a link between psychiatric medicines that get into the drinking water supply, and autism.
A story in the Spring, 2012, issue of The Trial Lawyer magazine takes a look at the flaws in the federal approval process that allow dangerous transvaginal mesh kits to be implanted in women, with disastrous results.
